Login or Register
Biomedical Learning Institute Taught by the Experts
Thought Leaders
Biomedical Learning Institute
Please Note: The Oncology Learning Center has changed its name to Biomedical Learning Institute
Co-Chairs

Dr. Bunn
Paul A. Bunn, Jr., MD
James Dudley Chair in Cancer Research
Professor, Medical Oncology
University of Colorado Denver
Aurora, CO
Executive Director, International Association for the Study of Lung Cancer
(IASLC)

Dr. Herbst
Roy S. Herbst, MD, PhD
Professor of Medicine
Chief, Section of Thoracic Medical Oncology
Department of Thoracic/Head and Neck Medical Oncology
Barnhart Family Distinguished Professor in Targeted Therapies
The University of Texas M. D. Anderson Cancer Center
Houston, TX

Dr. Langer
Corey J. Langer, MD
Professor of Medicine
Director, Thoracic Oncology
Division of Hematology-Oncology
Abramson Cancer Center
University of Pennsylvania
Philadelphia, PA
Vice Chair, Radiation Therapy Oncology Group
(RTOG)


Other Expert Faculty


Dr. Curran
Walter J. Curran, MD, FACR
Professor and Chair
Department of Radiation Oncology
Emory School of Medicine Chief Medical Officer
Winship Cancer Institute
Atlanta, GA
Chairman, Radiation Therapy Oncology Group
(RTOG)

Dr. Garon
Edward B. Garon, MD
Associate Professor of Medicine
Department of Medicine, Hematology/Oncology
Jonsson Comprehensive Cancer Center
Thoracic Oncology Program Area
University of California at Los Angeles School of Medicine
Los Angeles, CA

Dr. Gillison
Maura L. Gillison, MD, PhD
Jeg Coughlin Chair of Cancer Research
Professor of Internal Medicine & Epidemiology
Ohio State University Medical Center
Division of Hematology & Oncology
Columbus, OH

Dr. Gitlitz
Barbara J. Gitlitz, MD

Associate Professor of Clinical Medicine
Department of Medicine
USC Norris Comprehensive Cancer Center
Los Angeles, CA

Dr. Heymach
John V. Heymach, MD, PhD
Professor of Thoracic Head/Neck Medical Oncology
Professor of Cancer Biology
The University of Texas M. D. Anderson Cancer Center
Houston, TX

Dr. Kabbinavar
Fairooz Kabbinavar, MD

Professor of Medicine and Urologic Oncology
Henry Alvin and Carrie L. Meinhardt Chair, Kidney Cancer Research
Medical Director, Thoracic Oncology and Kidney Cancer Programs
Director Hematology-Oncology Fellowship Program
UCLA Institute of Urologic Oncology
Los Angeles, CA

Dr. Kelly
Karen Kelly, MD
Professor of Medicine
Deputy Director
University of Kansas
Kansas Masonic Cancer Research Institute
Kansas City, MO

Dr. Natale
Ronald. B. Natale, MD

Attending Physician
Cedars-Sinai Medical Center
Samuel Oschin Comprehensive Cancer Institute
Director of the Lung Cancer Research Program
Aptium Oncology
Los Angeles, CA

Dr. Sandler
Alan B. Sandler, MD
Professor of Medicine
Division Chief, Hematology & Medical Oncology
DeArmond Chair, Clinical Cancer Research
Oregon Health & Science University
Portland, OR
Co-Chair, Eastern Cooperative Oncology Group (ECOG)

Dr. Sequist
Lecia V. Sequist, MD, MPH

Assistant Professor, Department of Medicine
Harvard Medical School
Assistant Physician, Medicine,
Massachusetts General Hospital Cancer Center
Boston, MA

Dr. Simon
George R. Simon, MD, FACP, FCCP
Director, Thoracic Oncology Program
Department of Medical Oncology
Fox Chase Cancer Center
Philadelphia, PA

Dr. Socinski
Mark A. Socinski, MD

Professor of Medicine
Multidisciplinary Thoracic Oncology Program
Lineberger Comprehensive Cancer Center
University of North Carolina
Chapel Hill, NC

Dr. Wistuba
Ignacio I. Wistuba, MD
Professor
Departments of Pathology and
Thoracic/Head and Neck Medical Oncology
The University of Texas M. D. Anderson Cancer Center
Houston, TX

 

Personalized Lung Cancer

August 28, 2010

Hyatt Regency La Jolla at Aventine
San Diego, California

Co-Chairs

Paul A. Bunn, Jr., MD
James Dudley Chair in Cancer Research
Professor, Medical Oncology
University of Colorado Denver
Aurora, CO
Executive Director, International Association for the Study of Lung Cancer
(IASLC)

Roy S. Herbst, MD, PhD
Professor of Medicine
Chief, Section of Thoracic Medical Oncology
Department of Thoracic/Head and Neck Medical Oncology
Barnhart Family Distinguished Professor in Targeted Therapies
The University of Texas M. D. Anderson Cancer Center
Houston, TX

Corey J. Langer, MD
Professor of Medicine
Director, Thoracic Oncology
Division of Hematology-Oncology
Abramson Cancer Center
University of Pennsylvania
Philadelphia, PA
Vice Chair, Radiation Therapy Oncology Group
(RTOG)

 


Agenda Back to Top
August 28, 2010 – Saturday
7:00AM - 7:50AM Breakfast
7:00AM Registration
7:50AM Welcome and Introductions and CME Pre Test Paul Bunn
SESSION # 1 PERSONALIZING CHEMOTHERAPY-BASED CLINICAL STRATEGIES
CHAIR: PAUL BUNN
8:00AM Personalizing chemotherapy for NSCLC. Which strategies are ready for prime time and which are emerging soon? George Simon
8:20AM Personalizing systemic therapies for Head and Neck Cancers. What is optimal therapy today? Maura Gillison
8:40AM Maintenance chemotherapy-based personalized strategies for NSCLC. Ronald Natale
9:00AM New clinical applications of chemotherapy-based strategies plus radiation for thoracic malignancies. How can this combined-modality approach be personalized? Walter Curran
9:20AM Point-CounterPoint #1: Maintenance therapy should be a standard of care for the treatment of thoracic malignancies. Pro: Paul Bunn
Con: Corey Langer
9:40AM Session #1 Interactive Case Study Edward Garon
9:55AM Interactive Roundtable Panel Discussion Faculty & Learners
10:10AM BREAK  
SESSION #2 PERSONALIZING ANTI-ANGIOGENESIS-BASED CLINICAL STRATEGIES CHAIR: ROY HERBST
10:30AM How reliable are genomic markers and other predictive factors for predicting efficacy with anti-angiogenesis agents? Are we there? John Heymach
10:50AM Point-CounterPoint#2: Chemotherapy plus an angiogenesis inhibition strategy with a monoclonal antibody is a standard of care for patients eligible for this regimen. Pro: Karen Kelly
Con: Alan Sandler
11:10AM What are the optimal strategies using combinations of anti-angiogenesis monoclonal antibodies with other systemic therapies?” Alan Sandler
11:30AM How can we use anti-VEGF oral tyrosine kinase inhibition combined with other novel strategies for personalized therapy? Roy Herbst
11:50AM LUNCH WITH THE PROFESSORS Faculty & Learners
1:00PM Session #2 Interactive Case Study Fairooz Kabbinavar
1:15PM Interactive Roundtable Panel Discussion and Q & A Faculty & Learners
SESSION #3 PERSONALIZING ANTI-EGFR-BASED CLINICAL STRATEGIES CHAIR: PAUL BUNN
1:30PM Personalizing therapies for thoracic malignancies with anti-EGFR treatment strategies. A review of the practice changing and other key data. Paul Bunn
1:50PM Developing personalized treatment strategies for managing primary and secondary resistance to anti-EGFR therapy for NSCLC. Lecia Sequist
2:10PM How do we better involve our pathologists to help us do more effective EGFR and Kras testing? Ignacio Wistuba
2:30PM BREAK  
2:50PM How do we optimize anti-EGFR treatment strategies in the maintenance setting for patients with NSCLC? Mark Socinski
3:10PM Point-CounterPoint#3: All patients receiving anti-EGFR therapy for thoracic malignancies should be screened for the EGFR mutation. Pro: Paul Bunn
Con: Corey Langer
3:30PM Session #3 Interactive Case Study Barbara Gitlitz
3:45PM Interactive Roundtable Panel Discussion and Q & A Faculty & Learners
SESSION #4 INVESTIGATIONAL TARGETED THERAPIES IN LATE-STAGE DEVELOPMENT CHAIR: COREY LANGER
4:00PM Novel treatment strategies in late-stage development for NSCLC Roy Herbst
4:20PM Novel treatment strategies in late-stage development for SCLC Karen Kelly
4:40PM Final Interactive Roundtable Panel Discussion and Q & A Moderator: Corey Langer
4:55PM Concluding Remarks and CME Post Test Roy Herbst
5:00PM ADJOURN  
Educational Grants
Sincere appreciation is extended to the following companies for their generous commercial support of this educational meeting:

Genentech

OSI Oncology

Lilly

Boehringer Ingelheim

sanofi aventis

Abraxis

Bayer HealthCare Pharmaceuticals

Onyx Pharmaceuticals

Poniard

Biodesix

OBR
© 2012 Biomedical Learning Institute
1415 Legacy Drive, Suite 250 • Frisco, TX 75034 • Registration Phone: 214.269.2014 • Fax: 214.866.0311
Contact Us
Disclaimer: The material published on the Biomedical Learning Institute(BLI) Web site reflects the opinions and expertise of the authors and/or reviewers of the material, and not the opinions of the BLI, the CME provider, or the commercial supporters providing educational grants. The materials may address uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. Before using any therapeutic approaches reviewed in this material, a qualified physician should be consulted. Readers of this content should verify all information and data before treating patients or using any drugs or therapies described in any BLI materials. Click here for our Privacy Policy.